Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report issued on Monday,Benzinga reports. The brokerage currently has a $22.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. Finally, Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $6.50 on Monday. Y-mAbs Therapeutics has a one year low of $6.24 and a one year high of $20.90. The company has a 50 day moving average price of $10.32 and a 200 day moving average price of $12.13. The firm has a market capitalization of $291.13 million, a price-to-earnings ratio of -12.04 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period in the previous year, the company earned ($0.18) EPS. As a group, equities analysts forecast that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after buying an additional 3,416 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $133,000. SG Americas Securities LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $178,000. Finally, Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $210,000. 70.85% of the stock is currently owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.